SANZ A.I CyberSecurity Scoring
29/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Sandoz Australia & New Zealand in 2026.
No incidents recorded for Sandoz Australia & New Zealand in 2026.
No incidents recorded for Sandoz Australia & New Zealand in 2026.
Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”
Latest updates, reports, and threat intel affecting the global network.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to...
In a patent infringement case, the applicant may request an interlocutory injunction to prevent the respondent from engaging in acts that...
The recent decision in Regeneron Pharmaceuticals, Inc v Sandoz shows how a strong noninfringement position can be powerful to resisting a...
Regeneron/Bayer sought both an interlocutory injunction and final relief, and Sandoz cross-claimed for invalidity of the patent. On 3 September...
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical...
Introduction. No interlocutory injunction ('preliminary injunction' or 'PI') has been granted in any pharmaceutical patent dispute since 2018.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
On 1 September 2025, Australia's Pharmaceutical Benefits Scheme published its summary of changes for the month of September.
Sandoz named one of Australia's Best Workplaces™ – because great people build great partnerships. Sandoz has been named among Australia's Top...
A remote attacker who controls a container registry may be able to direct a client's token request to a host of the attacker's choice, and disclose the victim's registry credentials to that host. This vulnerability is addressed in containerization version 0.41.0.
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the djust live transport resolves the LiveView to mount from a client-supplied dotted path by calling `__import__(module_path, ...)`. The module is imported — running its top-level code (import side effects) — before the framework checks that the resolved object is a `LiveView` subclass and before any per-view authentication. The `LIVEVIEW_ALLOWED_MODULES` allowlist that should contain this is fail-open (`if allowed_modules:` — skipped when the setting is unset, the framework default) and uses loose `startswith` matching. An unauthenticated WebSocket client (the WS handshake does not require auth; per-view auth runs only after import + instantiate) can therefore send a `mount` / `live_redirect_mount` / `url_change` frame (or an SSE mount) with `view = "<any.importable.module>.AnyName"` and cause the server to import — and execute the top-level code of — any importable Python module by name. Version 1.0.7 fixes the issue with a fail-closed resolution gate (`djust._view_resolution.is_view_import_allowed`): a client view path resolves only if (a) its module is already loaded (`sys.modules` — so resolving runs no new code; URL-routed views loaded by URLconf at startup keep working with zero config) or (b) it matches `LIVEVIEW_ALLOWED_MODULES` on a module-segment boundary (explicit opt-in for lazily-imported views). The gate runs before `__import__` at all three sinks (+ defense-in-depth inside `_instantiate_view`). As a workaround, set `LIVEVIEW_ALLOWED_MODULES` to the narrow list of modules that contain your mountable LiveView classes. (Note: pre-patch the allowlist is `startswith`-matched and the import still precedes the subclass check, so this is mitigation, not a complete fix.)
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, djust's per-object authorization (`get_object` + `has_object_permission`, ADR-017) was enforced on the WebSocket mount and event paths but not on three other render entry points: (a) the initial HTTP GET render, (b) SPA `url_change` navigation, and (c) `{% live_render %}` embedded child views. An authenticated user could therefore view (and on some paths act on) an object they are not authorized for by loading the page directly, navigating to it via SPA url-change, or composing it as an embedded child — a classic IDOR / broken object-level access control on object-scoped views. This is fixed in djust 1.0.7. All render entry points now route through a shared `enforce_object_permission` chokepoint: HTTP GET returns 403, `url_change` emits a `permission_denied` frame and skips the render, and `{% live_render %}` (eager + lazy) refuses the embed. Views without a custom `get_object` are unaffected (no-op). No reliable workaround short of upgrading. Do not expose object-scoped views through the HTTP-GET / url_change / live_render paths until patched.
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the WebSocket `handle_mount` and `ViewRuntime._build_request` rebuild an `HttpRequest` via `RequestFactory().get(...)` with no `HTTP_HOST`, so `request.get_host()` defaulted to `"testserver"` on the live path. Host/subdomain/domain `TenantResolver`s then misresolved the tenant — `None` on the live path while the HTTP path resolved correctly. With `STRICT_MODE=False` the tenant-scoped managers returned unscoped rows (cross-tenant disclosure); with the default they returned an empty queryset (broken tenancy). This is fixed in djust 1.0.7. The handshake Host is extracted from the ASGI scope, validated against `ALLOWED_HOSTS` (the same logic as the CSWSH Origin gate, parsed with Django's `split_domain_port` so malformed Hosts are rejected at the boundary), and propagated — with the TLS scheme — into the reconstructed request, so live-path tenant resolution matches HTTP exactly. There is no known workaround on the live path short of upgrading. Users are most exposed when combined with `STRICT_MODE=False`.
djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, when a Django `Model` instance is assigned to a public view attribute, djust serialized it to the client with no sensitive-field denylist — sending fields such as `password` (the hash), privilege flags (e.g. `is_staff` / `is_superuser`), tokens, and other PII to the browser. Because exposing model objects to templates is a normal djust pattern, this could leak credentials/PII without the developer realizing the full object crossed the wire. This is fixed in djust 1.0.7. Model serialization applies a secure-by-default sensitive-field denylist (password/hash/token/secret-style fields and known privilege flags are withheld) with an identity-subset fallback. As a workaround, keep `Model` instances on `_private` attributes and expose only the specific fields needed, until patched.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.